Galectin Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.679
- Today's High:
- $1.8499
- Open Price:
- $1.68
- 52W Low:
- $1.02
- 52W High:
- $2.47
- Prev. Close:
- $1.67
- Volume:
- 53481
Company Statistics
- Market Cap.:
- $99.50 million
- Book Value:
- -0.896
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -103.61%
- Return on Equity TTM:
- -3727.95%
Company Profile
Galectin Therapeutics Inc had its IPO on 2002-09-09 under the ticker symbol GALT.
The company operates in the Healthcare sector and Biotechnology industry. Galectin Therapeutics Inc has a staff strength of 12 employees.
Stock update
Shares of Galectin Therapeutics Inc opened at $1.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.68 - $1.85, and closed at $1.79.
This is a +7.19% increase from the previous day's closing price.
A total volume of 53,481 shares were traded at the close of the day’s session.
In the last one week, shares of Galectin Therapeutics Inc have increased by +1.7%.
Galectin Therapeutics Inc's Key Ratios
Galectin Therapeutics Inc has a market cap of $99.50 million, indicating a price to book ratio of 207.6975 and a price to sales ratio of 0.
In the last 12-months Galectin Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Galectin Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Galectin Therapeutics Inc’s operating margin was 0% while its return on assets stood at -103.61% with a return of equity of -3727.95%.
In Q2, Galectin Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Galectin Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.65 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Galectin Therapeutics Inc’s profitability.
Galectin Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.4121. Its price to sales ratio in the trailing 12-months stood at 0.
Galectin Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $20.08 million
- Total Liabilities
- $9.95 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Galectin Therapeutics Inc ended 2025 with $20.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $20.08 million while shareholder equity stood at $-51127000.00.
Galectin Therapeutics Inc ended 2025 with $852000.00 in deferred long-term liabilities, $9.95 million in other current liabilities, 59000.00 in common stock, $-330271000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.97 million and cash and short-term investments were $17.97 million. The company’s total short-term debt was $43,000 while long-term debt stood at $60.36 million.
Galectin Therapeutics Inc’s total current assets stands at $19.47 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.98 million and inventory worth $0.
In 2025, Galectin Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Galectin Therapeutics Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $1.79
- 52-Week High
- $2.47
- 52-Week Low
- $1.02
- Analyst Target Price
- $11
Galectin Therapeutics Inc stock is currently trading at $1.79 per share. It touched a 52-week high of $2.47 and a 52-week low of $2.47. Analysts tracking the stock have a 12-month average target price of $11.
Its 50-day moving average was $1.59 and 200-day moving average was $1.58 The short ratio stood at 34.72 indicating a short percent outstanding of 0%.
Around 2909% of the company’s stock are held by insiders while 1208% are held by institutions.
Frequently Asked Questions About Galectin Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.